Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of dazucorilant (CORT113176) in healthy subjects
NCT04249323Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Jan 2020
- Primary completion
- Oct 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dazucorilant in amyotrophic lateral sclerosis (ALS) (5 arms), sponsored by Corcept Therapeutics. Primary endpoint: Number of Participants with One or More Adverse Events at Day 23. Started Jan 2020; status: completed.
02
Drugs
dazucorilant
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04249323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04249323.